Doxium is an exclusive vasoprotective used is Chronic Venous Insufficiency, In Hemorrhoids and in Diabetic Retinopathy.
The pathogenesis of hemorrhoids is multifactorial. Predisposing factors include heredity, portal hypertension, straining to defecate, and pregnancy. Internal hemorrhoids are classified into four groups.
First-degree internal hemorrhoids do not protrude, cannot be palpated by digital examination, and require anoscopy for diagnosis.
Second-degree hemorrhoids protrude with defecation, but reduce spontaneously.
Third-degree hemorrhoids protrude and require manual reduction.
Fourth-degree hemorrhoids are irreducibly prolapsed
etiology of hemorrhoids.pdf
Active principle: Calcium dobesilate. Capsule: Calcium dobesilate 500 mg, colour (E132), excipients for capsule.
Indications and usage:
Microangiopathies, in particular diabetic retinopathy. Clinical signs of chronic venous insufficiency in the lower limbs (Pain, cramps, paresthesia, oedema, stasis, dermatosis), as adjuvant in superficial thrombophlebitis. Haemorrhoidal syndrome, microcirculation disorders of arteriovenous origin.
Generally 500 to 1000 mg - 1 capsule once or twice a day - to be taken with the main meals. Treatment duration, which is generally between a few weeks and several months, depends on the disease and its evolution. Dosage should be adapted individually according to the severity of the case.
Not before the age of 12 years old.
Yes, safely as doxium is excreted half from kidney and half from liver.
Doxiproct plus ointment is used for all hemorrhoidal degrees: in 1st and 2nd degree for treatment, due to Calcium dobesilate and in 3rd and 4th degree as adjuvant to surgery.
Doxiproct ointment is used for all hemorrhoidal degrees: in 1st and 2nd degree for treatment due to Calcium dobesilate and in 3rd and 4th degree as adjuvant to surgery.
Minapharm Pharmaceuticals receives regulatory approval from the Paul-Ehrlich Institute for a phase 1 multi-center clinical trial in Germany for its Adalimumab biosimilar
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement
for the Commercialization of Multiple Biosimilar Candidates of Alvotech
in the Middle East and Africa
As a global leader in biotechnology & cellular engineering, ProBioGen-Minapharm
As a continuation of Minapharm unique series of "Expert Panel",
The meeting was chaired by Prof. Abdel-Shakour EL MOHAMADY.
Stay connected, subscribe to our newsletter for news and updates.